Tristel (AIM:TSTL) share news, analysis and insight

Make your money go further for just 25p per day

Tristel (TSTL)

Market: AIM · Sector: Health Care Equipment & Services

Company Insights

Accounting shenanigans | Dividends | Contract wins

27/03/2023

Encouraging contract wins but its accounting trickery which disturbs us

More on Tristel

Company Insights

Lofty valuations | Stretched balance sheets

21/02/2023

We shine a light on some lofty valuations - are they justified?

Company Insights

DUKE of hazard | Bonkers Bargain ahead again

12/12/2022

Updates include news of a worrying suspension

Company Insights

Growth constraints!

25/10/2022

Long-term growth for this company looks more challenging

Company Insights

Fantastic results from AIM elder

30/06/2022

Mundane products delivering magnificant results

Company Insights

Another Covid tester receives an upgrade

13/12/2021

But what of the post Covid world?

Company Insights

Healthcare winners from AIM!

18/10/2021

High growth excitement from AIM's healthcare sector

Company Insights

Bargains galore!

21/07/2021

Bonkers Bargains, Stonking Small Caps….and Slush Puppie!

Company Insights

Music to our ears

27/04/2021

Fabulous results from this fast-growing AIM favourite

Company Insights

Strong results to start the week

22/02/2021

Mobile payments and infection prevention lead the way

Company Insights

Hooray, a first ‘real’ profit for the online estate agents!

15/12/2020

Purplebricks offers a positive surprise, but will it continue to deliver?

Company Insights

Coronavirus impact: 19 Oct - boohoo tumbles (again) but others impress

19/10/2020

Fabulous results and updates here from lower profile AIM stars

Company Insights

AstraZeneca vs GlaxoSmithKline: a clear coronavirus winner?

31/07/2020

Financial results reveal which pharma giant has a better long-term strategy

Company Insights

Coronavirus impact: 22 July part 2 - pandemic winner offers overly cautious outlook

22/07/2020

Beneficiary of the pandemic is expertly manging expectations with latest update

Company Insights

Coronavirus impact assessment: 23 March

23/03/2020

Tough times for retailers as regulatory messages step up a gear

Company Insights

Coronavirus: potential winners from the almost-pandemic

25/02/2020

The outbreak highlights need for greater investment in infection control

Portfolio

Tristel delivers impressive financial results

16/10/2019

The infection prevention specialist has reported 18% revenue growth thanks to its burgeoning international presence

Podcasts

Investor’s Champion podcast: ISA time

03/04/2019

It's almost the end of the tax year which means the deadline for using up your ISA allowance is fast approaching. In this podcast we discuss how you can use your allowance.

Portfolio

Tristel looks to China for more growth

13/03/2019

The medical devices company thinks China’s focus on healthcare will provide the next chapter of growth

Company Insights

Tristel (AIM: TSTL) – cracking results and positive outlook bring out more upgrades

12/10/2015

The AIM quoted manufacturer of infection prevention and contamination control products, announces excellent ‘audited’ results for the year ahead of expectations with a resulting upgrade from the house broker.

Company Insights

Tristel plc (AIM: TSTL) – positive update, results ahead

21/05/2015

The AIM quoted manufacturer of infection prevention, contamination control and hygiene products has issued a positive trading update for the year ending 30 June 2015 with results anticipated to be…

ABOUT INVESTORS CHAMPION

Investor's Champion offers objective, incisive and forthright comment on quoted companies and personal finance. Our content addresses what we believe are the key issues in helping make your money go further.

Investor's Champion is a registered trade mark of Investors Champion Ltd. Investor's Champion Limited is a company registered in England and Wales under number 03577867 whose registered office is at c/o Cox Costello & Horne, 26 Main Avenue, Moor Park, England, HA6 2HJ.

All rights reserved. © 2007 - 2023